We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent Technologies and Anderson Forschung Group Collaborate on Quantitative Protein Assays
News

Agilent Technologies and Anderson Forschung Group Collaborate on Quantitative Protein Assays

Agilent Technologies and Anderson Forschung Group Collaborate on Quantitative Protein Assays
News

Agilent Technologies and Anderson Forschung Group Collaborate on Quantitative Protein Assays

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Technologies and Anderson Forschung Group Collaborate on Quantitative Protein Assays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies Inc. and Anderson Forschung Group LLC (AFG) have announced a collaboration to develop quantitative peptide assays to speed protein biomarker discovery and validation.

The collaboration will combine AFG’s stable isotope standards and capture by anti-peptide antibodies (SISCAPA) technology with Agilent’s 1200 Series HPLC-Chip and 6400 Series triple quadrupole mass spectrometers (MS).

The combination will be used to develop methods for measuring the amounts of large numbers of peptides in digests of complex samples such as plasma. The results will benefit both organizations, and financial details were not disclosed.

“We’re proud to be partnering with a thought leader like Dr. Anderson to develop improvements in clinical mass spectrometry,” said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. “One of the greatest challenges to delivering useful knowledge using the protein biomarker discovery paradigm is achieving effective, reproducible and highly sensitive peptide quantitation.”

“SISCAPA assays for candidate biomarkers can benefit substantially from the reproducibility and sensitivity of Agilent’s platform, and we look forward to optimizing this combination,” said Leigh Anderson, AFG’s chief executive officer.

The SISCAPA method utilizes antibody-coated magnetic beads and a rotary magnetic bead trap device to capture target peptides, which are then, measured using a nanoflow LC-MS/MS system. The goal is to measure the quantities of very small amounts of peptides in sample digests, creating a useful research tool with potential uses in advanced diagnostics.

The Agilent 1200 Series HPLC-Chip/MS system is a microfluidic platform that integrates LC columns, connection capillaries, and nanospray emitter in a polymer chip, providing uncompromised chromatographic performance, even with small sample input amounts. The credit card-sized device is inserted into Agilent’s HPLC-Chip Cube to interface with the MS. Chip loading, solvent and sample delivery, high pressure switching of flows, and chip positioning in the MS source are all automated.

The Agilent 6400 Series triple quadrupole LC/MS systems can provide femtogram-level sensitivity across a broad mass range. These instruments have earned a reputation for reliably quantitating trace organic compounds in complex matrices, such as drug metabolites, herbicide levels in food and contaminants in ground water.
Advertisement